Clinical Perspectives in Gastroparesis Mgmt. | Treatment Strategy
In this episode of Clinical Perspectives in Gastroparesis Management, Diana McFarlane, PA-C discusses her approach to symptoms that do not correlate with gastric emptying in patients with gastroparesis.
Diana McFarlane, PA-C
Gastroparesis Program Director and GI APP Lead
Virginia Mason Franciscan Health
IMPORTANT SAFETY INFORMATION
Enterra Therapy for treatment of chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
HUMANITARIAN DEVICE
Authorized by Federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated. What does this mean?